Shanghai Fosun New Drug Research Co., Ltd. plans to privatize Shanghai HENLIUS Biotechnology Co., Ltd. at a price of HK$24.60 per share. The proposal offers a cash option and a share option (limited to 8% of the total issued share capital). The cancellation price for non-listed shares is RMB 22.444794 per share. The independent director committee recommends that shareholders vote in favor of the merger plan.The H-share class shareholders meeting will be held on January 22, 2025, using a voting method. All H-share holders, except the offeror and its concert parties, are eligible to participate in the vote. Shareholders can appoint one or more proxies, with proxy appointment forms to be submitted 24 hours before the meeting (by 2:30 PM on January...Show More

Shanghai Fosun New Drug Research Co., Ltd. plans to privatize Shanghai HENLIUS Biotechnology Co., Ltd. at a price of HK$24.60 per share. The proposal offers a cash option and a share option (limited to 8% of the total issued share capital). The cancellation price for non-listed shares is RMB 22.444794 per share. The independent director committee recommends that shareholders vote in favor of the merger plan.The H-share class shareholders meeting will be held on January 22, 2025, using a voting method. All H-share holders, except the offeror and its concert parties, are eligible to participate in the vote. Shareholders can appoint one or more proxies, with proxy appointment forms to be submitted 24 hours before the meeting (by 2:30 PM on January 21, 2025). H-share transfer registration will be suspended from January 17 to 22, 2025.Important dates include: the H-share registration deadline is at 4:30 PM on January 16, 2025; the temporary shareholders meeting and H-share class shareholders meeting will be held on January 22, 2025; the deadline for submitting selection forms is February 28, 2025; the final deadline is April 30, 2025. Shareholders will bear the costs of attending, including Transportation and Lodging. All mentioned dates and times are in Peking time.